Compare Equinor ASA (EQNR) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs McKesson Corporation — how do they compare? Equinor ASA trades at $35.58 (market cap $82.75B), while McKesson Corporation trades at $840.54 (market cap $93.23B). The key difference: Equinor ASA and McKesson Corporation are close in size by market cap, and Equinor ASA pays the higher dividend (4.24%). Which is the better fit depends on your goals.
| EQNR | MCK | |
|---|---|---|
Market Cap | $82.75B | $93.23B |
Sector | Energy | Health |
52-Week High | $42.40 | $995.69 |
52-Week Low | $22.41 | $659.01 |
Enterprise Value | $94.51B | $97.87B |
Dividend Yield | 4.24% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $35.78, down 1.13% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed recent earnings, beating expectations in Q1 2026 but missing in Q3 2025. Recent news highlights strategic investments in Norwegian Continental Shelf projects and a share buy-back program, while exiting non-core operations like Japan offshore wind.
EQNR presents a moderate investment case with a low P/E of 16.23 and strong cash flow, but faces risks from declining net income margins and volatile energy markets. Analyst sentiment is mixed with a 30% buy rating, suggesting cautious optimism amid execution and commodity price uncertainties.
MCK trades at $836.49, up 4.12% in the last session, with a neutral technical signal and strong analyst consensus. Recent earnings consistently beat expectations, with Q1 2026 EPS of $11.69 surpassing the $11.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins remain thin at 1.18%. The stock is supported by positive cash flow trends and a dividend payout scheduled for July 2026.
The outlook is positive, driven by earnings momentum and a $932.83 consensus price target implying 11.5% upside. Risks include low profitability margins and high liabilities, but institutional sentiment is bullish with 80% buy ratings. Investors should weigh growth in specialty pharma against execution and regulatory pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
